Explore the Agenda
Personalis is a provider of advanced genomic sequencing and analytics solutions that support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Their patented ACE (Accuracy & Content Enhanced) Technology forms the foundation of all Personalis products. ACE Technology improves every individual step in the next-generation sequencing (NGS) process, from nucleic acid extraction to sequencing assays, to data analytics. This makes it possible for them to achieve augmented coverage of difficult-to-sequence genomic regions that are missed with the use of conventional sequencing techniques.
Using this comprehensive approach, they can provide you with genomic data of the highest quality and accuracy to drive immuno-oncology clinical and biomarker discovery programs, thus enabling the rational design and development of effective cancer immunotherapies.
Register your interest today to join Personalis for an in-depth, interactive engager session and explore how ultra-sensitive MRD detection and advanced genomic sequencing are reshaping oncology clinical trials. Discover how these technologies can be integrated into your programs to strengthen patient selection, generate earlier signals, and accelerate therapeutic development.
Personalis Engager
3:30 pm Interactive Session
Previous editions brought together Key Opinion Leaders from consortia, biotech, healthcare and large pharma for the Engager session, Accelerating Clinical Timelines: Using Ultra-Sensitive MRD to Accelerate Clinical Development, driving focused discussion on how MRD can meaningfully compress development timelines and sharpen trial decision making.
With limited capacity available, register your interest to attend today.